Gilead faces lawsuit over hepatitis C drug pricing

Philadelphia's Transportation Authority has filed a lawsuit against Gilead Sciences Inc. over the pricing of its hepatitis C drug.

Sovaldi is a highly effective pill treatment for the most common form of hepatitis C without the injections and unpleasant side effects of earlier treatments.

Gilead has been selling a 12-week treatment of Sovaldi in the United States for approximately $84,000, or $1,000 per pill. That has raised complaints by insurers, politicians and patient advocates, particularly because millions of Americans could benefit from the drug.

The complaint was filed in . It says Sovaldi's cost prohibits many patients from getting treatment and accuses Gilead of "unjust enrichment" that violates .

The Foster City, California, company could not be reached immediately for a comment Wednesday.

Explore further

Gilead to license generic version of Sovaldi (Update)

© 2014 The Associated Press. All rights reserved.

Citation: Gilead faces lawsuit over hepatitis C drug pricing (2014, December 10) retrieved 27 January 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors